Mutation
Oct 24, 2016
Sarepta’s Unusual Journey
Before approving an investigational drug, safety and effectivity needs to be proven. Something different happened with Sarepta’s Muscular dystrophy drug Eteplirsen, as its luck changed completely when the U.S. Food and Drug Administration on 19th September 2016 approved Sarepta Therapeutics' Exondys 51 (eteplirsen) ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
